PERCEPTIVE ADVISORS LLC - 27 Dec 2023 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Reporting relationship: 10%+ Owner
Issuer ticker: VRCA
Reported as of: 27 Dec 2023
Net transaction value: +$2,305,132
SEC form: 4
Accepted by SEC: 29 Dec 2023, 17:27:30 UTC
Prior SEC filing: 22 Dec 2023
Next SEC filing: 12 Jan 2024
Source filing: View source filing
Reporting owner signature: /s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member

Key filing fact

PERCEPTIVE ADVISORS LLC filed Form 4 for Verrica Pharmaceuticals Inc. (VRCA) on 29 Dec 2023.

Key facts

This page summarizes PERCEPTIVE ADVISORS LLC's Form 4 filing for Verrica Pharmaceuticals Inc. (VRCA).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 29 Dec 2023, 17:27.

Change

Previous filing in this sequence was filed on 22 Dec 2023.
Current net transaction value: +$2,305,132.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRCA transaction

Common Stock

Purchase

Transaction value: $574,027
Shares: +79,726
Change %: +1.2%
Price: $7.20
Shares after: 6,857,292
Date: 27 Dec 2023
Ownership: See Footnote
Footnotes: F1, F4

VRCA transaction

Common Stock

Purchase

Transaction value: $892,901
Shares: +126,116
Change %: +1.8%
Price: $7.08
Shares after: 6,983,408
Date: 28 Dec 2023
Ownership: See Footnote
Footnotes: F2, F4

VRCA transaction

Common Stock

Purchase

Transaction value: $838,204
Shares: +115,774
Change %: +1.7%
Price: $7.24
Shares after: 7,099,182
Date: 29 Dec 2023
Ownership: See Footnote
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.90 to $7.50 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.

Footnote F2

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.76 to $7.30 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.

Footnote F3

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.02 to $7.32 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.

Footnote F4

The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.